Multimodal therapy for complete regression of malignant melanoma using constrained nonlinear optimal dynamic inversion

2014 ◽  
Vol 13 ◽  
pp. 198-211 ◽  
Author(s):  
C.M. Sakode ◽  
R. Padhi ◽  
S. Kapoor ◽  
V.P.S. Rallabandi ◽  
P.K. Roy
Keyword(s):  
Malignant Melanoma ◽  
Multimodal Therapy ◽  
Dynamic Inversion ◽  
Complete Regression ◽  
Optimal Dynamic

scholarly journals Active vibration suppression of non-linear beams using optimal dynamic inversion

2009 ◽  
Vol 223 (5) ◽  
pp. 657-672 ◽  
Author(s):  
Sk F Ali ◽  
R Padhi
Keyword(s):  
Vibration Suppression ◽  
Control Variable ◽  
Linear Partial Differential Equation ◽  
Spatial Domain ◽  
Dynamic Inversion ◽  
Control Force ◽  
Control Approach ◽  
Closed Form Solutions ◽  
Non Linear ◽  
Optimal Dynamic

Euler-Bernoulli beams are distributed parameter systems that are governed by a non-linear partial differential equation (PDE) of motion. This paper presents a vibration control approach for such beams that directly utilizes the non-linear PDE of motion, and hence, it is free from approximation errors (such as model reduction, linearization etc.). Two state feedback controllers are presented based on a newly developed optimal dynamic inversion technique which leads to closed-form solutions for the control variable. In one formulation a continuous controller structure is assumed in the spatial domain, whereas in the other approach it is assumed that the control force is applied through a finite number of discrete actuators located at predefined discrete locations in the spatial domain. An implicit finite difference technique with unconditional stability has been used to solve the PDE with control actions. Numerical simulation studies show that the beam vibration can effectively be decreased using either of the two formulations.

Complete Regression of Primary Malignant Melanoma

2008 ◽  
Vol 30 (2) ◽  
pp. 178-181 ◽  
Author(s):  
Patrick O Emanuel ◽  
Meghan Mannion ◽  
Robert G Phelps
Keyword(s):  
Malignant Melanoma ◽  
Primary Malignant Melanoma ◽  
Complete Regression

Hyperthermic Isolation-perfusion with Melphalan. A Preliminary Appraisal of Local and General Effects in Malignant Melanoma

1977 ◽  
Vol 63 (3) ◽  
pp. 289-298 ◽  
Author(s):  
F. J. Lejeune ◽  
M. Mathieu ◽  
Y. Kenis
Keyword(s):  
Malignant Melanoma ◽  
Adjuvant Treatment ◽  
Systemic Chemotherapy ◽  
Distant Metastases ◽  
Stage Ii ◽  
Complete Regression ◽  
In Transit

Ten hyperthermic isolation-perfusions with melphalan were performed for invasive malignant melanoma of the limbs. Four cases at stage II and with in transit metastases (up to 15 cm in diameter) had a complete regression. However, no improvement of survival was noticed: 4 out of 5 stage II patients who died, within 1 year after perfusion, developed a generalized disease. Systemic chemotherapy was administered in 3 patients after perfusion, but they died from distant metastases. The need for an adequate adjuvant treatment added to isolation perfusion is discussed.

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma

Blood ◽  
2001 ◽  
Vol 97 (7) ◽  
pp. 1942-1946 ◽  
Author(s):  
John E. Janik ◽  
Langdon L. Miller ◽  
Edward L. Korn ◽  
Diane Stevens ◽  
Brendan D. Curti ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Complete Regression ◽  
Protective Effects ◽  
Gm Csf ◽  
Grade 3 ◽  
To Receive

Abstract We conducted a phase II randomized trial of recombinant granculocyte-macrophage colony-stimulating factor (GM-CSF) administered before topotecan chemotherapy to determine whether it could prevent myelosuppression and to determine the antitumor activity of this topoisomerase I inhibitor in 53 patients with metastatic malignant melanoma and renal cell cancer. All patients received GM-CSF after topotecan at a dose of 250 μg/m2 daily for at least 8 days. Patients randomly assigned to receive GM-CSF priming were treated with GM-CSF at 250 μg/m2 twice daily for 5 days before treatment. Twenty-five patients were randomly assigned to receive GM-CSF priming and 28 to receive topotecan without priming. The primary analysis was restricted to the protective effects seen during the first cycle of therapy. Grade 4 neutropenia occurred in 8 of 23 patients (35%) and grade 3 neutropenia in 5 of 23 patients (22%) randomized to GM-CSF priming, whereas 18 of 26 (69%) and 5 of 26 (19%) patients experienced grade 4 or 3 neutropenia, respectively, without GM-CSF priming (P = .0074). The mean duration of neutropenia was reduced by GM-CSF priming: grade 3 neutropenia from 5.2 ± 0.7 to 2.8 ± 0.7 days (P = .0232) and grade 4 neutropenia from 2.7 ± 0.6 to 1.1 ± 0.4 days (P = 0.0332). The protective effects of GM-CSF extended to the second cycle of treatment. The incidence of febrile neutropenia was also reduced. Chemotherapy-induced anemia and thrombocytopenia were similar in both groups. One partial response was seen in a patient with melanoma, and one patient with renal cell cancer had complete regression of pulmonary metastases and was rendered disease-free by nephrectomy.

Sign in / Sign up

Export Citation Format

Share Document